造血干细胞移植治疗多发性骨髓瘤的研究进展

Advances on the hematopoietic stem cell transplantation for the treatment of multiple myeloma

造血干细胞移植（HSCT）是治疗多发性骨髓瘤（MM）的一线方案。自体造血干细胞移植（auto-HSCT）可提高患者缓解率，延长生存期。首次auto—HSCT后，未获得非常好的部分缓解及以上疗效的患者，可行二次auto—HSCT进一步改善疗效。异基因造血干细胞移植（allo—HSCT）具有治愈MM的潜能，但移植相关死亡率高，患者生存并未获益。减低剂量的allo—HSCT相关死亡率低，但复发率高，也未显示出生存优势。序贯auto—HSCT及allo—HSCT也未使患者生存明显获益。总结近期HSCT的研究进展。

Hematopoietic cell transplantation is frontline treatment of multiple myeloma （MM）. Autologous hematopoietic stem cell transplantation （auto-HSCT） could improve remission rate, prolong survival time, the tandem auto-HSCT is able to make patients get further benefits for patients not achieving at least very good partial remission after the first auto-HSCT. Allologous hematopoietic stem cell transplantation （allo- HSCT） is potentially able to cure multiple myeloma, but patients achieve less benefit because of high transplant-related mortality （TRM）. The TRM is low after reduced-intensity conditioning allo-HSCT, but which exhibit no survival benefit. Moreover, patients achieve no survival benefit after tandem auto-HSCT and allologous reduced-intensity conditioning transplantation. This paper reviewes recent studies about HSCT in MM.